Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00106301 · ClinicalTrials.gov registry record · Phase 2
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
A Phase 2 study of Prostatic Neoplasms and Carcinoma, Renal Cell, sponsored by Celgene.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
- 5
- Study locations
NCT00106301: Completed Phase 2 study of Prostatic Neoplasms and Carcinoma, Renal Cell, sponsored by Celgene.
NCT00106301 is a Phase 2 study of Prostatic Neoplasms and Carcinoma, Renal Cell that has completed, run by Celgene. The registered enrollment target is 2 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (100% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00106301, a Phase 2 study of Prostatic Neoplasms and Carcinoma, Renal Cell, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable disease on prior Fujisawa sponsored FK228 clinical trials.
Conditions Studied
Interventions
- DRUG FK228 (romidepsin)
Study Locations (5)
California
- City of Hope National Medical Center - Duarte
Florida
- University of Florida - Gainesville
Illinois
- University of Chicago - Chicago
Washington
- Seattle Cancer Care Alliance - Seattle
Other
- Royal Marsden Hospital - Sutton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2004-04-01 |
| Est. Completion | 2006-09-01 |
| Phase | Phase 2 |
What the finished NCT00106301 record still lists
NCT00106301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which FK228 (romidepsin) is the first listed.
NCT00106301 lists 5 locations in 5 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT00106301 about?
NCT00106301 is a clinical study titled "Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228". The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable disease on prior Fujisawa sponsored FK228 clinical trials.
What is the current status of trial NCT00106301?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2004-04-01. Estimated completion is 2006-09-01.
What conditions does trial NCT00106301 study?
This clinical trial studies the following conditions: Prostatic Neoplasms, Carcinoma, Renal Cell.
What interventions are being tested in trial NCT00106301?
The interventions under investigation include: FK228 (romidepsin) (DRUG).
Who is sponsoring clinical trial NCT00106301?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00106301 being conducted?
This trial has 5 study locations across California, Florida, Illinois, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00106301's enrollment target sits among peer trials
2 65th of 65 higher than 1 of 65 other Prostatic Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
RECRUITING · Phase 2
-
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
RECRUITING · Phase 2
-
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI